Targeting Ewing Sarcoma (ES), Osteosarcoma (OS) and Neuroblastoma (NB) with Anti-MCAM Chimeric Antigen Receptor (CAR) Modified Natural Killer (NK) Cells

Authors

W Luo, New York Medical CollegeFollow
A Gardenswartz, New York Medical CollegeFollow
Y Chu, New York Medical CollegeFollow
J M. Rosenblum, New York Medical CollegeFollow
J Ayello, New York Medical CollegeFollow
M Marcondes
W W. Overwijk
T P. Cripe
K A. Cassady
D A. LeeFollow
M S. Cairo, New York Medical CollegeFollow

Author Type(s)

Faculty

Document Type

Abstract

Publication Date

2022

DOI

10.1002/pbc.29735

Journal Title

Pediatric Blood and Cancer

Department

Pediatrics

Abstract

Background: Pediatric patients with metastatic ES, OS and NB have a dismal average 5-year survival (

Recommended Citation

Luo, W., Gardenswartz, A., Chu, Y., Rosenblum, J. M., Ayello, J., Marcondes, M., Overwijk, W. W., Cripe, T. P., Cassady, K. A., Lee, D. A., & Cairo, M. S. (2022). Targeting Ewing Sarcoma (ES), Osteosarcoma (OS) and Neuroblastoma (NB) with Anti-MCAM Chimeric Antigen Receptor (CAR) Modified Natural Killer (NK) Cells. Pediatric Blood and Cancer, 69 (Suppl. 2), S220-S221. https://doi.org/10.1002/pbc.29735